Previous 10 | Next 10 |
DUBLIN , July 31, 2019 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today reported financial results for the second quarter ended June 30, 2019 . Revenue for the second quarter of 2019 was $26.2 million . Second quarter operating lo...
DUBLIN , July 25, 2019 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company") today announced that it will release financial results for the period ended June 30, 2019 and provide a business update prior to market open on Wednesday, July 31,...
Krones I've been following Krones ( KRNNF ) ( KRNTY ) for many years. This German hidden champion (EUR 1.7B market cap, free float <45% of this) builds large and small plants for filling and packaging, process engineering, and intralogistics as well as IT solutions for the food and bevera...
New data from a Phase 2 clinical trial evaluating Theravance Biopharma's ( TBPH +1.9% ) ampreloxetine (TD-9855) in patients with neurogenic orthostatic hypotension (nOH) showed a treatment benefit. The results were presented at the European Neurology Congress in London. More news on: ...
DUBLIN , July 22, 2019 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company") today reported new data from the Company's Phase 2 clinical trial of ampreloxetine (TD-9855) in patients with neurogenic orthostatic hypotension (nOH) in an oral...
Black swans don't always come alone The following is a fascinating story about two "black swan" events happening at the same time, but one remaining somewhat under the radar, at least until very recently. The combined effect of the two has caused a severe sell-off in the shares of Theravan...
DUBLIN , June 18, 2019 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company") today reported new data from the Company's Phase 2 clinical trial of ampreloxetine (TD-9855) in patients with neurogenic orthostatic hypotension (nOH) in a poste...
DUBLIN and HERTFORDSHIRE, England and PITTSBURGH , June 14, 2019 /PRNewswire/ -- Theravance Biopharma Ireland Limited, a subsidiary of Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma") and Mylan N.V. (NASDAQ: MYL) ("Mylan") today announced the expansion of t...
Theravance Biopharma ( TBPH -0.2% ) appoints Andrew Hindman as CFO & SVP of the company More news on: Theravance Biopharma, Inc., , Read more ...
DUBLIN , June 4, 2019 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company") today announced the appointment of Andrew Hindman as Senior Vice President and Chief Financial Officer. Mr. Hindman brings nearly 25 years of life science...
News, Short Squeeze, Breakout and More Instantly...
Theravance Biopharma Inc. Company Name:
TBPH Stock Symbol:
NASDAQ Market:
Theravance Biopharma to Report First Quarter 2024 Financial Results on May 13, 2024 PR Newswire DUBLIN , April 29, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its first quarter 2024 financial results and provide a business update af...
2024-04-24 22:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...